Demant benefits from AI hearing aid boom, shares extend strong quarterly rally
26.06.2026 - 12:26:54 | ad-hoc-news.de
By Thomas Klein, Operations & Strategy desk. Reviewed prior to publication on 2026-06-26, 10:25.
Demant (DK0010268440) is set for its best quarter in 26 years on the Copenhagen exchange. The hearing-aid specialist benefits from strong demand for a new AI-based device, with Bloomberg reporting a 39 percent gain in the shares since the beginning of April.Bloomberg report on Demant's AI-fueled rally
AI product drives turnaround
According to Bloomberg, Demant's latest hearing aid equipped with artificial intelligence has helped the company recover from a sector-wide slump that pushed the stock to a more than three-year low in February 2026.Bloomberg report on Demant's AI-fueled rally Since early April, the shares have advanced 39 percent, marking the strongest quarterly performance since 2000 on OMX Copenhagen.
The rebound comes as the hearing care sector faced stagnant demand and intensifying competition from peers such as Sonova and GN Store Nord earlier this year.Bloomberg report on Demant's AI-fueled rally Demant's new AI line appears to be gaining traction in key markets including the United States and Europe, supporting a marked improvement in investor sentiment.
Analysts lift price targets
The positive share-price development is mirrored in recent analyst actions. On 25 June 2026, Goldman Sachs reiterated its Buy rating on Demant and lifted the price target to 290 Danish kroner from 275 kroner, according to MarketScreener.Goldman Sachs target increase for Demant The US bank cited stronger growth prospects in the core hearing-aid business.
Jefferies has also maintained a Buy rating on the US-traded Demant ADR and recently raised its target price to 44.07 US dollars, as reported by brokerage platform Moomoo.Jefferies update on Demant ADR Earlier in June, Bank of America delivered a double-upgrade of Demant to Buy, noting sector growth and Demant's positioning, with Investing.com highlighting a roughly 3 percent share gain on the day of that call.Investing.com note on BofA upgrade
All news and analysis on the Demant shares
Price data, previous announcements and additional analyst commentary on Demant are compiled in the dedicated topic overview at ad-hoc-news.de.
How Demant earns its money
Demant generates most of its revenue from hearing healthcare, particularly through its Oticon-branded hearing aids and related accessories.Demant investor presentation The group also operates hearing care clinics and sells diagnostics equipment, creating an integrated offering across the hearing-loss value chain.
Where the shares trade today
The Demant shares (DK0010268440) last traded on OMX Copenhagen on 2026-06-26 at around 292 Danish kroner.
Key data on the Demant shares
- Company: Demant A/S
- ISIN: DK0010268440
- WKN: 893484
- Ticker: DEMANT
- Trading venue: OMX Copenhagen
- Price (as of 2026-06-26, 10:25): 292 DKK
- Market cap: 222 billion DKK (as of 2026-06-26)
- Sector / industry: Health Care - Medical Devices & Equipment
- Index membership: OMX Copenhagen 25
- Next earnings date: not officially scheduled
This article is for informational purposes only and does not constitute investment advice, a recommendation to buy or sell securities, or any other form of financial guidance. Figures and dates are based on publicly available sources believed to be reliable but cannot be guaranteed for accuracy or completeness.
